PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience

Loza, Sara Murias; Rueda, RM Alcobendas; Camba, Agustín Remesal; Salcedo, Dora Pascual; Peralta, Jesús; Muñoz, R. Merino

doi:10.1186/1546-0096-11-s2-p264

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported the presence of anti-drug antibodies in 43 % of pediatric patients receiving infliximab for juvenile idiopathic arthritis and other pediatric rheumatic diseases, measured by an in-house ELISA [28]. Two recent studies reported the measurement of anti-drug antibody levels in pediatric rheumatology patients treated with ADA: Imagawa et al [32] analyzed 25 Japanese pediatric patients with JIA treated with ADA, finding a 24 % frequency of anti-ADA antibodies using a double-antigen ELISA, while Murias et al [33] observed 32 % anti-ADA antibody positivity on the same number of children, using a two-site bridging ELISA. In the latter study, anti-ADA antibodies correlated with disease activity.…”

Section: Sample Sera Screeningmentioning

confidence: 97%

Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization

et al. 2015

View full text Add to dashboard Cite

Adalimumab (ADA) is a TNF-α blocker drug antibody fully humanized and thus indistinguishable in structure and function from natural human IgG1, used in the juvenile idiopathic arthritis (JIA) treatment. Immunogenicity against the drug has been frequently detected in treated patients, and the presence of anti-ADA antibodies is correlated to treatment failure or lower clinical remission. Herein, we measured by surface plasmon resonance (SPR) both the binding and the affinity of anti-ADA antibodies to the ADA-immobilized biosensor. The binding of anti-ADA antibodies was evaluated by testing sera from ADA-treated patients (n = 30), untreated patients (n = 9), and healthy donors (n = 20) in the SPR biosensor. The optimal cut-off point was defined using the receiver operating characteristic curve (ROC-curve) analysis with 79 % (60.28 to 92.01 %, 95 % CI) sensitivity, 99 % (88.06 to 100.0 %, 95 % CI) specificity, and a positive likelihood ratio of 23. The area under the curve was 0.9298 (p < 0.0001). The apparent affinity of anti-ADA antibodies from pediatric patients' sera was measured, analyzing the interaction of anti-drug antibodies using whole sera, enriched IgG fractions, and isolated anti-ADA antibodies. The immobilized drug ADA interacted with purified antibodies at low affinities (10(-6) M > K D > 10(-9) M). Graphical Abstract Adalimumab immobilized on the biosensor chip surface detects specific anti-drug antibodies in treated patients' sera.

show abstract

Section: Sample Sera Screeningmentioning

confidence: 97%